Physician profile
Nicolette Stephens
NPI 1740654458
$4,283.02
in general payments reported to CMS, 2019-2025
22 companies · $1,973 in 2025
The $1,973 reported for 2025 was more than what 95% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $621 · 2022: $528 · 2023: $21.21 · 2024: $1,140 · 2025: $1,973.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,048 · Education: $86.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,047.61 |
| Education | $86.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $856.44 | 2024-2025 | Tremfya, Simponi Aria |
| Astrazeneca Pharmaceuticals Lp | $628.03 | 2021-2025 | Breztri, Lokelma |
| Amgen INC. | $450.71 | 2024-2025 | Otezla, Repatha, Repatha |
| Novo Nordisk INC | $436.54 | 2021-2025 | Ozempic |
| Bayer Healthcare Pharmaceuticals INC. | $368.08 | 2021-2025 | |
| Abbvie INC. | $231.00 | 2024-2025 | |
| Abbott Laboratories | $161.24 | 2025 | Thoratec Heartmate 3 Lvas Implant Kit |
| Teva Pharmaceuticals USA, INC. | $135.91 | 2024 | Austedo Xr |
| Sanofi-Aventis U.S. LLC | $133.36 | 2025 | |
| Axsome Therapeutics, INC. | $133.16 | 2024-2025 | Auvelity |
| Evoke Pharma, INC. | $125.00 | 2025 | |
| Esperion Therapeutics, INC. | $125.00 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $122.63 | 2021 | |
| Corcept Therapeutics | $113.02 | 2024 | Korlym |
| Dynavax Technologies Corporation | $97.76 | 2025 | Heplisav-B |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $44.37 | 2025 | Cologuard Collection Kit |
| Ibsa Pharma INC. | $24.72 | 2025 | Tirosint, Flector, Licart |
| Ucb, INC. | $22.02 | 2024 | Bimzelx |
| Merz North America, INC. | $21.21 | 2023 | Xeomin |
| Astellas Pharma US INC | $21.05 | 2024 | Veozah |
| Pfizer INC. | $19.94 | 2024 | |
| Allergan, INC. | $11.83 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicolette Stephens listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.